As Teva wins U.S. approval for GSK Advair copy, main fight yet to come
By Ben Hirschler LONDON (Reuters) – Israel's Teva Pharmaceutical Industries has won U.S. approval to market a copy of GlaxoSmithKline&039;s best-selling Advair inhaler, although the real battle is still to come. Teva&039;s version of GSK&039;s blockbuster medicine, called AirDuo RespiClick, is not directly substitutable for Advair and is only approved for asthma, while Advair is also widely used for chronic obstructive pulmonary disease (COPD). Teva said on Monday it would launch AirDuo later this year.
